Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Monday, June 30, 2025.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2025 (2025-06-30): -375.71%.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
-349.66%
RETURN ON EQUITY (ROE) AVG 3Y
-197.40%
RETURN ON EQUITY (ROE) AVG 5Y
-99.10%
RETURN ON EQUITY (ROE) AVG 10Y
-130.59%
RETURN ON EQUITY (ROE) AVG 15Y
-106.31%
RETURN ON EQUITY (ROE) AVG 20Y
-100.76%
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Oncolytics Biotech Inc.
Market Cap
$60.02M
Return on Equity (ROE)
N/A
TTM Avg
-349.66%
3Y Avg
-197.40%
5Y Avg
-99.10%
Market Cap
$60.42M
Return on Equity (ROE)
N/A
TTM Avg
-866.00%
3Y Avg
-422.47%
5Y Avg
-312.54%
Market Cap
$60.24M
Return on Equity (ROE)
-76.75%
TTM Avg
-53.49%
3Y Avg
-5.79%
5Y Avg
-19.88%
Market Cap
$59.18M
Return on Equity (ROE)
-30.21%
TTM Avg
-215.14%
3Y Avg
-180.32%
5Y Avg
47.11%
Market Cap
$58.44M
Return on Equity (ROE)
N/A
TTM Avg
-285.38%
3Y Avg
-206.98%
5Y Avg
-151.57%
Market Cap
$62.78M
Return on Equity (ROE)
-492.89%
TTM Avg
-50.27%
3Y Avg
-279.07%
5Y Avg
-249.48%
Market Cap
$58.94M
Return on Equity (ROE)
N/A
TTM Avg
71.44%
3Y Avg
1810.59%
5Y Avg
1190.90%
Market Cap
$58.43M
Return on Equity (ROE)
-82.38%
TTM Avg
-68.06%
3Y Avg
-60.95%
5Y Avg
-49.61%
Market Cap
$62.62M
Return on Equity (ROE)
-136.82%
TTM Avg
-201.41%
3Y Avg
-55.55%
5Y Avg
-39.58%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Oncolytics Biotech Inc. (ONCY) | $60.02M | N/A | -349.66% | -197.40% | -99.10% |
| Fractyl Health, Inc. (GUTS)vs › | $60.42M | N/A | -866.00% | -422.47% | -312.54% |
| Kalaris Therapeutics Inc (KLRS)vs › | $60.24M | -76.75% | -53.49% | -5.79% | -19.88% |
| Xilio Therapeutics, Inc. (XLO)vs › | $59.18M | -30.21% | -215.14% | -180.32% | 47.11% |
| PDS Biotechnology Corporation (PDSB)vs › | $58.44M | N/A | -285.38% | -206.98% | -151.57% |
| Heron Therapeutics, Inc. (HRTX)vs › | $62.78M | -492.89% | -50.27% | -279.07% | -249.48% |
| MiNK Therapeutics, Inc. (INKT)vs › | $58.94M | N/A | 71.44% | 1810.59% | 1190.90% |
| Adicet Bio, Inc. (ACET)vs › | $58.43M | -82.38% | -68.06% | -60.95% | -49.61% |
| RenovoRx, Inc. (RNXT)vs › | $62.62M | -136.82% | -201.41% | -55.55% | -39.58% |
| Boundless Bio, Inc. (BOLD)vs › | $57.76M | -58.99% | -51.19% | -1.82% | 11.74% |
ROE
N/A
ROA
-393.7%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-06-30 | -375.71% |
| 2025-03-31 | -416.65% |
| 2024-12-31 | -496.10% |
| 2024-09-30 | -305.33% |
| 2024-06-30 | -154.50% |
| 2024-03-31 | -123.61% |
| 2023-12-31 | -99.34% |
| 2023-09-30 | -112.31% |
| 2023-06-30 | -118.43% |
| 2023-03-31 | -95.65% |
| 2022-12-31 | -96.52% |
| 2022-09-30 | -91.07% |
| 2022-06-30 | -80.95% |
| 2022-03-31 | -75.85% |
| 2021-12-31 | -73.34% |
| 2021-09-30 | -65.72% |
| 2021-06-30 | -62.30% |
| 2021-03-31 | -63.39% |
| 2020-12-31 | -88.18% |
| 2020-09-30 | -157.19% |
| 2020-06-30 | -126.42% |
| 2020-03-31 | -128.05% |
| 2019-09-30 | -533.94% |
| 2019-06-30 | -478.39% |
| 2019-03-31 | -305.21% |
| 2018-12-31 | -285.36% |
| 2018-09-30 | -187.21% |
| 2018-06-30 | -155.82% |
| 2018-03-31 | -357.67% |
| 2017-12-31 | -184.95% |
| 2017-09-30 | -126.90% |
| 2017-06-30 | -112.82% |
| 2017-03-31 | -202.16% |
| 2016-12-31 | -144.70% |
| 2016-09-30 | -85.23% |
| 2016-06-30 | -67.81% |
| 2016-03-31 | -68.64% |
| 2015-12-31 | -59.07% |
| 2015-09-30 | -54.09% |
| 2015-06-30 | -55.04% |
| 2015-03-31 | -68.20% |
| 2014-12-31 | -141.15% |
| 2014-09-30 | -143.77% |
| 2014-06-30 | -135.23% |
| 2014-03-31 | -128.21% |
| 2013-12-31 | -108.38% |
| 2013-09-30 | -96.14% |
| 2013-06-30 | -90.76% |
| 2013-03-31 | -90.66% |
| 2012-12-31 | -244.49% |
| 2012-09-30 | -172.89% |
| 2012-06-30 | -115.03% |
| 2012-03-31 | -80.46% |
| 2011-12-31 | -99.94% |
| 2011-09-30 | -66.21% |
| 2011-06-30 | -53.69% |
| 2011-03-31 | -39.94% |
| 2010-12-31 | -52.45% |
| 2010-09-30 | -104.08% |
| 2010-06-30 | -72.87% |
| 2010-03-31 | -58.53% |
| 2009-12-31 | -48.23% |
| 2009-09-30 | -199.30% |
| 2009-06-30 | -178.85% |
| 2009-03-31 | -367.13% |
| 2008-12-31 | -209.27% |
| 2008-09-30 | -162.04% |
| 2008-06-30 | -111.45% |
| 2008-03-31 | -61.16% |
| 2007-12-31 | -53.65% |
| 2007-09-30 | -48.19% |
| 2007-06-30 | -43.51% |
| 2007-03-31 | -40.01% |
| 2006-12-31 | -47.30% |
| 2006-09-30 | -32.99% |
| 2006-06-30 | -30.01% |
| 2006-03-31 | -28.62% |
| 2005-12-31 | -25.00% |
| 2005-09-30 | -32.54% |
| 2005-06-30 | -36.33% |
| 2005-03-31 | -33.33% |
| 2004-12-31 | -33.98% |
| 2004-09-30 | -39.87% |
| 2004-06-30 | -31.34% |
| 2004-03-31 | -42.79% |
| 2003-12-31 | -32.76% |
| 2003-09-30 | -39.47% |
| 2003-06-30 | -44.13% |
